In MM cells, silibinin has been demonstrated to be useful in the treatment of MM via inhibition of proliferation and an increase in apoptosis via inhibiting PI3K/Akt-mTOR signaling pathways [37]. This evidence concerns the gene AKT1 and Miyoshi myopathy.